Clarapath develops robotics, machine vision and digital automation tools to modernize how pathology laboratories process tissue, with its SectionStar system positioned as an all‑in‑one tissue sectioning and transfer solution. SectionStar is described as the first (pending U.S. launch) system that increases capacity, reliability and consistency while reducing the need for highly skilled labor. The company says its automation captures and aggregates new data to improve downstream digital pathology and diagnostic review. Clarapath cites a strained laboratory environment driven by severe labor shortages, rising caseloads and antiquated manual workflows as rationale for its products; the article notes more than 12 million human and veterinary biopsies are performed annually in the U.S. The company operates medical device development in Hawthorne, NY and runs a CLIA‑certified laboratory serving clinical and non‑clinical organizations. With this financing, Clarapath plans to accelerate commercialization of SectionStar and expand sales, service, precision manufacturing and R&D to build an end‑to‑end 'lab of the future.' Clarapath develops SectionStar, a fully automated, all‑in‑one tissue sectioning and transfer system that standardizes and accelerates the preparation of glass slides for pathology. SectionStar consolidates manual cutting, quality control, and decision steps to produce more consistent tissue sections and support AI‑driven analysis. The company says the system increases throughput, reduces reliance on skilled labor, and generates richer datasets for molecular mapping and precision‑medicine research. Clarapath works with research and clinical customers today, including Northwell Health and The Ellison Institute, and operates a CLIA‑certified clinical research organization that offers whole slide imaging and automated image processing. The company plans to launch SectionStar first in the non‑clinical market in the near term while targeting the larger clinical market as its ultimate goal. Recent financing will support product development, team growth, and expanded sales and service efforts.

Total raised

$52M

Funding rounds

2

Latest round

Series B

Latest activity

Jul 2024